Researchers have significantly boosted the development of the innovative solution for ATTR-CM, leveraging the compound. Preliminary patient data indicates significant outcomes for individuals suffering by this debilitating disease. The effort highlights BridgeBio's dedication to treating significant patient demands in the heart disease field. Attr